Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)

Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. oatautta/Shutterstock.com Pantginis maintains a long-term view based on the company’s differentiated VK2735 oral and injectable formulations. This view come ...